Cerebrolysin for Cognition & Stroke: What the Evidence Says

Cerebrolysin is a porcine-brain-derived mixture of low-molecular-weight peptides and amino acids, marketed as a neurotrophic and neuroprotective agent and used in Russia, Eastern Europe, China, and other post-Soviet and Asian countries for acute ischemic stroke, vascular dementia, Alzheimer's disease, and traumatic brain injury^[4]. It is not approved by the US Food and Drug Administration (FDA) for any indication. The controlled evidence is genuinely mixed: the most rigorous synthesis — a 2023 Cochrane review of 7 randomized trials and 1773 stroke patients — found no convincing benefit on death and, critically, a statistically significant increase in non-fatal serious adverse events with cerebrolysin^[1]. Smaller Cochrane reviews in vascular dementia and separate meta-analyses in Alzheimer's show cognitive signals, but all are rated very low certainty, are heavily industry-funded, and do not establish a net clinical benefit. This article presents the evidence — including the Cochrane conclusions — without overselling the drug in either direction. See the peptides hub for related neurotrophic and performance peptides.

What is cerebrolysin? A porcine brain in a vial

Cerebrolysin (brand name FPF 1070; manufactured by EVER Neuro Pharma, Austria) is produced by enzymatic hydrolysis of porcine (pig) cerebral cortex proteins^[4]. The result is a sterile aqueous solution containing approximately 25% low-molecular-weight active peptides — including fragments with sequence homology to known neurotrophic factors such as BDNF, NGF, CNTF, and IGF-1 — and 75% free amino acids^[4]. The low molecular weight (under 10,000 daltons) allows the active fractions to cross the blood-brain barrier, which is the pharmacological rationale for the drug.

The proposed mechanisms include: stimulation of neuronal differentiation and survival; reduction of excitotoxicity in ischemic conditions; modulation of amyloid-β metabolism and tau phosphorylation in Alzheimer's models^[7]; and enhancement of synaptic plasticity^[5]. These mechanisms are well-described in preclinical models. The question — which Cochrane reviewers have examined repeatedly — is whether they translate into clinically meaningful benefit in human patients at meaningful effect sizes, with an acceptable safety profile.

Where cerebrolysin is approved — and where it isn't

Cerebrolysin holds regulatory approval in more than 50 countries including Russia, Ukraine, China, Germany, Austria, and several countries across Eastern Europe, Central Asia, and the Middle East. In those jurisdictions it is licensed for indications including acute ischemic stroke, dementia (vascular and Alzheimer's type), and traumatic brain injury^[1]. It is typically administered as a slow intravenous infusion over 10–21 days in clinical settings, not as a pill or subcutaneous injection.

In the United States, cerebrolysin has never received FDA approval and is not listed on DailyMed. It has not completed a Phase III pivotal trial for any indication in the US regulatory pathway. Purchasing cerebrolysin online or importing it for personal use sits in a legal grey zone — FDA enforcement discretion applies to small personal imports, but the product has no verified identity, purity, or sterility assurance when purchased from unregulated online sources. Importing a non-FDA-approved biological product carries real risk: contamination, incorrect labeling, and the absence of any medical oversight if an adverse reaction occurs.

Acute ischemic stroke: what the 2023 Cochrane review found

The most rigorous and up-to-date synthesis of cerebrolysin evidence in stroke is the 2023 Cochrane review by Ziganshina et al. (7th update, PMID 37818733)^[1]. It included 7 randomized controlled trials with 1773 participants, comparing cerebrolysin or cerebrolysin-like agents (started within 48 hours of stroke onset) versus placebo. Critically, none of the included studies reported on the primary outcome of poor functional outcome — defined as death or dependence at end of follow-up — the most clinically relevant endpoint for stroke interventions. That absence alone is a major limitation.

What the 2023 review did find, with moderate-certainty evidence:

• All-cause death: no difference. Cerebrolysin probably results in little to no difference in all-cause death (RR 0.96, 95% CI 0.65–1.41; 6 trials, 1689 participants; moderate certainty)^[1].
• Non-fatal serious adverse events: statistically significant increase. The total number of people with non-fatal serious adverse events was higher in the cerebrolysin group (RR 2.39, 95% CI 1.10–5.23; 3 trials, 1335 participants; moderate certainty). At the most common dosing schedule (30 mL for 10 days; cumulative dose 300 mL) the risk ratio was even higher (RR 2.87, 95% CI 1.24–6.69; 2 trials, 1189 participants)^[1].
• Total SAEs: probably no difference overall (RR 1.16, 95% CI 0.81–1.66), driven by the reduction in fatal SAEs offsetting the increase in non-fatal SAEs^[1].
• Industry funding concern. The manufacturer of cerebrolysin supported three of the included multicentre studies — either fully or by providing the drug, placebo, randomisation codes, research grants, or statisticians. Two studies were rated at high risk of other bias^[1].

"Moderate-certainty evidence indicates that Cerebrolysin or Cerebrolysin-like peptide mixtures derived from cattle brain probably have no beneficial effect on preventing all-cause death in acute ischaemic stroke… Moderate-certainty evidence also indicates a potential increase in non-fatal serious adverse events with Cerebrolysin use."

— Ziganshina LE et al., Cochrane Database Syst Rev 2023 (PMID 37818733)

The bottom line for stroke: the most clinically meaningful outcome — death or dependence — was never even measured in the available trials. On the outcomes that were measured, there is no mortality benefit and a real safety signal on non-fatal serious adverse events. This is not a basis for concluding cerebrolysin works for stroke.

Vascular dementia: small signals, very low certainty

The 2019 Cochrane review of cerebrolysin for vascular dementia (Cui et al., PMID 31710397) included 6 RCTs with 597 participants^[2]. The trials were largely conducted in China, Russia, and Romania; most were industry-funded. Doses and durations of cerebrolysin treatment varied across trials; follow-up ranged from 15 days to 3 years.

Pooled analyses showed apparent benefits on cognitive function (SMD 0.36, 95% CI 0.13–0.58; 3 trials, 420 participants) and global function (RR 2.69, 95% CI 1.82–3.98; 2 trials, 379 participants), with no signal of harm in reported adverse event data. However, the Cochrane authors rated all of these findings as very low certainty — the lowest GRADE rating — due to high risk of bias in the included papers and heterogeneity across trials^[2]. A 2025 narrative review noted that the potential role of cerebrolysin in vascular dementia remains plausible mechanistically, but the clinical evidence base has not grown since the 2019 update^[5].

The Cochrane authors concluded that "if there are benefits of Cerebrolysin, the effects may be too small to be clinically meaningful" — and that cerebrolysin "continues to be used and promoted as a treatment for vascular dementia, but the supporting evidence is weak."^[2]

Alzheimer's disease: short-term signal, uncertain long-term benefit

The most methodologically careful synthesis of cerebrolysin in Alzheimer's disease is a 2015 meta-analysis by Gauthier et al. (PMID 25832905), which pooled individual patient data and aggregate data from 6 randomized double-blind placebo-controlled trials in mild-to-moderate Alzheimer's, all using 30 mL/day intravenous cerebrolysin^[3].

Key findings from the Gauthier 2015 meta-analysis^[3]:

• Cognitive function at 4 weeks: statistically significant benefit (SMD −0.40, 95% CI −0.66 to −0.13; p = 0.003). A small-to-moderate effect size.
• Cognitive function at 6 months: benefit was not statistically significant (SMD −0.37, 95% CI −0.90 to 0.16; p = 0.17). The confidence interval crosses zero.
• Global clinical change at 6 months: significant on the odds ratio measure (OR 4.98, 95% CI 1.37–18.13; p = 0.015), but the very wide confidence interval limits interpretability.
• Safety: comparable to placebo across included trials. No serious safety signal in the Alzheimer's meta-analysis — in contrast to the stroke Cochrane findings.

The honest read: there is a detectable short-term cognitive signal in Alzheimer's trials, but it does not consistently hold at 6 months, all trials used the same 30 mL/day IV protocol (not a format available outside clinical settings), and most were sponsored by the manufacturer. A 2022 exploratory study found that cerebrolysin plus donepezil modulated amyloid-β and tau levels in plasma neuronal extracellular vesicles^[7], suggesting a mechanistic rationale, but this is not evidence of clinical benefit at the patient level. Cerebrolysin is not approved for Alzheimer's disease in the United States.

Traumatic brain injury: one positive RCT in mild TBI

A 2013 double-blind placebo-controlled randomized trial by Chen et al. (PMID 23656173) enrolled patients with mild TBI and found that cerebrolysin was associated with enhanced cognitive recovery over the follow-up period compared with placebo^[6]. The study is a single small trial, and no Cochrane-level systematic review of cerebrolysin for TBI exists. Some countries include TBI in the licensed indications; US evidence does not support regulatory approval. The result is hypothesis-generating, not practice-changing on its own.

Evidence summary by indication

The honest verdict

Cerebrolysin occupies an unusual position in neurology: it is a licensed, clinically used drug in more than 50 countries, with decades of use and a plausible neurotrophic mechanism — yet its most rigorous evidence synthesis (the 2023 Cochrane review for stroke^[1]) found no convincing benefit on the outcomes that matter most and a real safety signal. The Cochrane reviews for vascular dementia^[2] rate the available evidence as very low certainty, meaning that our confidence in the apparent positive results is minimal. The Alzheimer's meta-analysis^[3] shows a signal at 4 weeks that is not maintained at 6 months.

This does not mean cerebrolysin is definitively ineffective — the evidence base has significant gaps (the stroke trials never measured death/dependence; the dementia trials were largely industry-funded with high risk of bias). It means that the existing controlled evidence does not establish net clinical benefit, and in stroke it raises a safety concern. For patients in countries where cerebrolysin is legally prescribed, the risk-benefit decision rests with specialist clinicians who can weigh individual factors. For people in the US considering obtaining it through grey-market channels: the controlled evidence does not support that choice, and the regulatory and safety risks are real.

This article is educational and is not medical advice. All claims referencing trial results are drawn from peer-reviewed publications indexed in PubMed (citations verified live against the PubMed database on 2026-07-07). The Cochrane reviews cited (PMIDs 37818733 and 31710397) are the highest-quality systematic syntheses of the cerebrolysin clinical trial literature and represent the current state of evidence. The meta-analysis (PMID 25832905) is an industry-associated pooled analysis and was interpreted accordingly. US regulatory status reflects FDA records as of the article date. Always consult a licensed medical provider before using any unapproved drug or injectable product.